Project Grant R01HL185323
Award Date 8/17/26
Completion Date 4/30/30
Dollars Obligated $747K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $867,656 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 1, 2026, to develop and apply comparative effectiveness evidence methods for evaluating medical therapies in heart failure with mildly reduced ejection fraction (HFMREF). The award funds completion of the largest echocardiography registry in the world and application of regression discontinuity...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $614,843 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research examining the relationship between indexed exercise blood pressure and adverse vascular and ventricular remodeling as risk factors for heart failure with preserved ejection fraction (HFPEF). The research investigates whether the ratio of peak...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $736,411 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of neutrophil-derived resistin-like molecule G (RELMG) in arrhythmia pathogenesis and prevention. The research examines RELMG's mechanism of action and therapeutic potential in reducing ventricular tachycardia and atrial fibrillation following...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $121,345 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2026. The award funds development of positron emission tomography (PET) imaging of oxidized collagen as a biomarker for myocardial fibrosis in heart failure with preserved ejection fraction (HFpEF). The project focuses on targeted PET imaging probes that bind...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $797,124 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop pseudouridine synthase 7 (PUS7) as a novel therapeutic target for preventing adverse cardiac remodeling and treating heart failure. The project, R01HL188041, advances preclinical findings demonstrating that PUS7 inhibition activates RNA autophagy and provides...
- The National Heart, Lung, and Blood Institute awarded Duke University $778,772 on August 18, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate metabolic and contractile dysfunction in heart failure with preserved ejection fraction. The research focuses on understanding the mechanistic link between mitochondrial impairment and loss of muscle strength and power in HFPEF, a systemic disorder affecting 3–4 million U.S. patients predominantly older women. The...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital (MGH) a $709,917 Project Grant (CFDA 93.837: Cardiovascular Diseases Research) effective September 17, 2025, through July 31, 2030, to conduct genomic research on peripartum cardiomyopathy (PPCM). The research will investigate the genetic factors underlying PPCM, a leading cause of maternal mortality characterized by sudden heart muscle weakening during late...
- The National Heart, Lung, and Blood Institute awarded the University of Massachusetts Medical School $1,281,208 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate thromboxane A₂ generation as a biomarker and mediator of heart failure risk. The award is a Project Grant with assistance type classified as R01HL185859. The research measures urinary thromboxane B₂ metabolites indexed to renal function (TXB₂-M_GFR) across approximately 17,000...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $770,247 on July 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define the mechanistic basis of airway metaplastic response through investigation of stem cell heterogeneity, YAP signaling, and EGFR signaling pathways. The research addresses the cellular source and molecular mechanisms governing squamous and mucous metaplasia—two...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $186,840 under CFDA 93.837 Cardiovascular Diseases Research on July 3, 2026, for advanced analysis of high-resolution cardiac diffusion tensor imaging (DTI). The funded work develops and applies DTI phenomapping, a voxel-level quantitative analysis approach for cardiac magnetic resonance imaging that resolves distinct microstructural patterns in...